Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

21
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
21
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

22
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
22
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

1.4K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The increasing use of cognitive enhancing drugs by those with ADHD and neurotypical individuals: Societal demands, lifestyle preferences, and ethical issues.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Response to interpreting cross-sectional comparisons of menopausal status and brain outcomes.

Psychological medicine·2026
Same author

Development of an automated, imaging-based preoperative screening model for early identification of malnutrition in an abdominal surgery cohort.

medRxiv : the preprint server for health sciences·2026
Same author

ASO Visual Abstract: Comparing Resident Team Performance in Complex Surgical Oncology: A Single-Institution Cohort Study.

Annals of surgical oncology·2026
Same author

Shifts in the brain sex continuum in major depressive disorder: Evidence for a persistent neurobiological marker.

Journal of affective disorders·2026
Same author

Comparing Resident Team Performance in Complex Surgical Oncology: A Single-Institution Cohort Study.

Annals of surgical oncology·2026

Related Experiment Video

Updated: Apr 28, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

25.1K

Targeting impulsivity in Parkinson's disease using atomoxetine.

Angie A Kehagia1, Charlotte R Housden2, Ralf Regenthal3

  • 11 Department of Neuroimaging, Institute of Psychiatry, King's College London, London SE5 8AF, UK angie.kehagia@gmail.com.

Brain : a Journal of Neurology
|June 5, 2014
PubMed
Summary

Enhancing noradrenaline levels with atomoxetine improved cognitive functions, including response inhibition and decision-making, in Parkinson's disease patients. This suggests targeting noradrenergic dysfunction may offer new therapeutic strategies for cognitive deficits in Parkinson's disease.

More Related Videos

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
09:12

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

9.6K
The 5-Choice Serial Reaction Time Task: A Task of Attention and Impulse Control for Rodents
09:43

The 5-Choice Serial Reaction Time Task: A Task of Attention and Impulse Control for Rodents

Published on: August 10, 2014

45.7K

Related Experiment Videos

Last Updated: Apr 28, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

25.1K
Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
09:12

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

9.6K
The 5-Choice Serial Reaction Time Task: A Task of Attention and Impulse Control for Rodents
09:43

The 5-Choice Serial Reaction Time Task: A Task of Attention and Impulse Control for Rodents

Published on: August 10, 2014

45.7K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cognitive Psychology

Background:

  • Noradrenergic dysfunction, stemming from locus coeruleus degeneration, is implicated in Parkinson's disease (PD) cognitive impairments.
  • Noradrenaline influences cognitive processes beyond dopamine's effects in PD, particularly in dysexecutive symptoms.
  • Direct investigation of noradrenergic enhancement for PD-related cognitive deficits is lacking.

Purpose of the Study:

  • To directly assess the impact of noradrenergic enhancement on cognitive and behavioral functions in Parkinson's disease.
  • To investigate the effects of atomoxetine, a selective noradrenaline reuptuptake inhibitor, on impulsivity and decision-making in PD patients.

Main Methods:

  • A double-blind, randomized, placebo-controlled study involving 25 Parkinson's disease patients.
  • Administration of 40 mg atomoxetine or placebo, followed by a comprehensive neuropsychological test battery.
  • Assessment of response inhibition, decision-making, attention, planning, and verbal short-term memory.

Main Results:

  • Atomoxetine significantly improved stopping accuracy in response inhibition tasks.
  • The drug reduced impulsivity and risk-taking behavior in gambling-related decision-making tasks.
  • Atomoxetine enhanced sustained attention and problem-solving abilities, with effects correlating with plasma concentration.

Conclusions:

  • Targeting noradrenergic dysfunction with atomoxetine shows promise in ameliorating specific cognitive and behavioral deficits in Parkinson's disease.
  • These findings support the hypothesis that noradrenaline plays a crucial role in dopaminergically independent cognitive functions in PD.
  • Further research is warranted to explore atomoxetine's therapeutic potential in managing Parkinson's disease cognitive impairments.